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Abstract
Background: The extracellular domains of cytokine receptors are released during inflammation, but little is known
about the shedding of Toll-like receptors (TLR) and whether they can be used as diagnostic biomarkers.
Methods: The release of sTLR2 and sTLR4 was studied in in-vitro stimulations, as well as in-vivo during experimental
human endotoxemia (n = 11, 2 ng/kg LPS), and in plasma of 394 patients with infections (infectious mononucleosis,
measles, respiratory tract infections, bacterial sepsis and candidemia) or non-infectious inflammation (Crohn’s disease,
gout, rheumatoid arthritis, autoinflammatory syndromes and pancreatitis). Using C-statistics, the value of sTLR2 and
sTLR4 levels for discrimination between infections and non-infectious inflammatory diseases, as well as between viral
and bacterial infections was analyzed.
Results: In-vitro, peripheral blood mononuclear cells released sTLR2 and sTLR4 by exposure to microbial ligands.
During experimental human endotoxemia, plasma concentrations peaked after 2 hours (sTLR4) and 4 hours
(sTLR2). sTLR4 did not correlate with cytokines, but sTLR2 correlated positively with TNFα (rs = 0.80, P < 0.05), IL-6
(rs = 0.65, P < 0.05), and IL-1Ra (rs = 0.57, P = 0.06), and negatively with IL-10 (rs = -0.58, P = 0.06), respectively. sTLR4 had
a similar area under the ROC curve [AUC] for differentiating infectious and non-infectious inflammation compared
to CRP: 0.72 (95% CI 0.66-0.79) versus 0.74 (95% CI 0.69-0.80) [P = 0.80], while sTLR2 had a lower AUC: 0.60 (95%
CI 0.54-0.66) [P = 0.0004]. CRP differentiated bacterial infections better from viral infections than sTLR2 and sTLR4:
AUC 0.94 (95% CI 0.90-0.96) versus 0.58 (95% CI 0.51-0.64) and 0.75 (95% CI 0.70-0.80), respectively [P < 0.0001 for both].
Conclusions: sTLRs are released into the circulation, and suggest the possibility to use sTLRs as diagnostic tool in
inflammatory conditions.
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Background
Toll-like receptors (TLRs) are germline-encoded receptors
that recognize microbial structures called pathogen-
associated molecular patterns (PAMPs), either alone or
in combination with co-receptors. Besides regulating
innate and adaptive immune responses, TLR signaling
plays an important role in the pathogenesis of several
inflammatory diseases, and tight regulation is crucial
in order to prevent hyperinflammation [1,2]. Immune
signaling is regulated at multiple levels, and the release
of extracellular domains of immune receptors such as
cytokine receptors represents an important regulatory
mechanisms [3]. Similar negative regulation accounts
for modulation of TLR function [1,2], and soluble
forms of TLR2 and TLR4 have been recently described
[4,5]. The release of these soluble proteins increases
upon cell activation and they exert inhibitory activity
on TLR signaling [4,5]. Soluble forms of TLRs have
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been detected in pleural fluid, amniotic fluid, saliva,
breast milk and plasma [4,6-10].
Timely knowledge of the etiology of inflammatory
conditions is crucial. Not only does it facilitate appropriate
treatment, but also unnecessary interventions may be
avoided. In light of the critical shortage of new antibiotics,
reduction in antibiotic prescription is warranted.
The concept of measuring soluble pattern recognition
receptors (PRRs) for the diagnosis of infections has been
previously proposed for the TLR4-coreceptor CD14
[11,12]. However, analysis of soluble TLRs have up till
now only been used in the diagnostic workup of pleural
effusion and intra-amniotic infections [8-10,13].
The aim of the present study was to gain more insight
into the release of sTLR2 and sTLR4 in-vitro and to
investigate the kinetics of monocytic TLR2 and TLR4
expression and plasma levels of their soluble counter-
parts during experimental endotoxemia (intravenous
LPS administration in healthy volunteers). Furthermore,
we hypothesized that sTLR2 and sTLR4, being soluble
forms of receptors that play pivotal roles in pathogen rec-
ognition by cells of the innate immune system, are differ-
entially released during various inflammatory diseases,
with higher levels in inflammatory conditions of infectious
origin. As such, we evaluated the ability of sTLR2 and
sTLR4 levels to discriminate between infectious and non-
infectious inflammatory pathologies.
Methods
In-vitro studies
Peripheral blood mononuclear cells (PBMCs) were
isolated from buffy coats of healthy individuals after
informed consent. Briefly, PBMCs were isolated by
density gradient centrifugation using Ficoll-Paque PLUS
(GE Healthcare, Zeist, The Netherlands) and collecting
the white interphase. Cells were washed twice in cold PBS
and concentrations were adjusted to 5 × 106 cells/ml in
RPMI-1640, supplemented 2 mM L-glutamine, 1 mM
pyruvate and 50 μg/ml gentamicin (GIBCO Invitrogen,
Carlsbad, CA). Mononuclear cells (5 × 105) in a 100-μl
volume were added to round-bottom 96-well plates
(Greiner, Nurnberg, Germany) and incubated with either
100 μl of culture medium (negative control), or LPS from
E. coli O55:B5 (10 μg/ml; Sigma-Aldrich, St Louis, MO),
Pam3Cys (10 μg/ml) or heat-killed E. coli ATCC 35218
(107 micro-organisms/ml). After 24 hour incubation at
37°C, the supernatants were stored at -80°C until meas-
urement of sTLR2, sTLR4 and IL-6.
Experimental human endotoxemia
This study was part of a larger endotoxin trial registered
at the ClinicalTrials.gov registry under the number
NCT00783068 which was approved by the local ethics
committee of the Radboud university medical center
[14]. The 11 healthy male volunteers included in the
present study provided written informed consent. Briefly,
subjects were prehydrated during 1 h before LPS adminis-
tration by infusion of 1.5 L 2.5% glucose/0.45% saline solu-
tion, followed by 150 ml/h starting at the time of LPS
administration until 6 h afterwards and 75 ml/h until the
end of the experiment. US Reference Escherichia coli
endotoxin (LPS derived from E. coli O:113; Clinical Center
Reference Endotoxin, National Institutes of Health,
Bethesda, Md) was administered as an intravenous
bolus (2 ng/kg). EDTA anticoagulated blood was col-
lected from an arterial line.
Flow cytometry for membrane TLR2 and TLR4 expression
In order to determine expression of TLR2 and TLR4,
blood was collected in EDTA-containing vacutainers. The
following directly conjugated mouse anti-human anti-
bodies were used: TLR2: CD282 PE (mouse IgG2a, TLR
2.1 clone, eBioscience, San Diego, CA), TLR4: CD284 PE-
Cy7 (mouse IgG2a, HTA125 clone eBioscience, San Diego,
CA), and CD14 ECD (mouse IgG2a, RMO52 clone Immu-
notech, Beckman Coulter, Marseille, France). Isotype and
fluorochrome matched controls from Beckman Coulter
were used. Cell buffer solution was used containing 0.5%
Bovine Serum Albumin in Phosphate Buffered Saline and
0.1% sodium azide. Rabbit serum (Invitrogen, Carlsbad,
CA) for blocking was diluted to 20% with cell buffer solu-
tion. Red blood cell lysis was performed using 0.075 M
ammonium chloride (NH4Cl, pH7.4), freshly prepared.
1 ml of blood was mixed with 20 ml of NH4Cl lysing solu-
tion and was left at room temperature for 10 minutes.
After centrifuging for 5 minutes at 500 g the supernatant
was discarded. The cell pellet was resuspended in 50 ml of
PBS and centrifuged again. After this washing step the cell
pellet was resuspended in 0.5 ml cell buffer solution.
0.1 ml of this cell suspension was mixed with 0.1 ml 20%
rabbit serum and left at room temperature for 10 min.
Subsequently, cells were incubated with the appropriate
antibody concentration mixture for 15 min in the dark
at room temperature. After washing, samples were re-
suspended in 0.5 ml cell buffer solution and analyzed on
a Beckman Coulter FC500 flow cytometer (Beckman
Coulter, Miami, FL). Monocytes were gated in a Side
Scatter vs. CD14 plot. Fluorochrome matched isotype
controls, non-stained samples, as well as cells incubated
with only a secondary antibody, were used to set the
photo multiplier detectors. The TLR2 and TLR4 expression
was analyzed within CD14+ monocytes.
Biomarker study
Plasma concentrations of sTLR2 and sTLR4 were mea-
sured in healthy controls, and two groups of patients and
compared to that of the most used inflammatory bio-
marker, C-reactive protein (CRP). EDTA anticoagulated
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blood from the various groups of patients was prospectively
collected during planned laboratory blood assessment for
clinical purposes, or was available from previous clinical
studies, as indicated. Plasma was obtained by centrifugation
for 10 minutes at 2000 g. The study has been carried out in
the Netherlands in accordance with the applicable rules
concerning the review of research ethics committees and
informed consent. Inclusion and exclusion criteria for
the inflammatory disorders are shown in Table 1. Table 2
shows the demographic characteristics of the healthy
controls and the patients included.
The first group consisted of patients with infectious
diseases in whom plasma was obtained ≤24 hours after
presentation: viral lower respiratory tract infections
(LRTI) (n = 25; Table 3), measles [15] (n = 43), infectious
mononucleosis caused by either Epstein-Barr virus (EBV)
[16] or cytomegalovirus (CMV) infection (n = 16), bacter-
ial and viral respiratory co-infections (n = 20; Table 3),
bacterial sepsis [17], stratified into sepsis, severe sepsis
and septic shock [18] (n = 156), and candidemia [19]
(n = 26). The second group comprised of patients with
non-infectious inflammation: Crohn’s disease (n = 15), gout
(n = 36), autoinflammatory syndromes (n = 15), rheumatoid
arthritis (n = 20), and pancreatitis [20] (n = 22). Patients
with autoinflammatory syndromes consisted mainly of
patients with well-known, genetically confirmed auto-
inflammatory diseases, like hyperimmunoglobulin-D
syndrome, familial Mediterranean fever, Muckle-Wells
syndrome and tumor necrosis factor receptor-1 associated
syndrome (TRAPS). Pancreatitis was of biliary origin in
45%, none developed necrosis and all had negative blood
cultures. Samples were taken ≤24 hours after presentation,
except for Crohn’s disease and reumatoid arthritis. Those
were taken during an exacerbation of the disease (Table 1).
The disease activity of rheumatoid arthritis was measured
with Disease Activity Score (DAS) in 28 joints (DAS28)
[21]. The definition of active rheumatoid arthritis is a
DAS28 > 3.2. The mean DAS28 was 4.49 (range 3.40-6.40,
of whom 7 patients had a score >5.1, indicating high dis-
ease activity).
Table 1 Description of included inflammatory disorders
Inflammatory disorder Inclusion criteria Exclusion criteria
Crohn’s disease Compatible endoscopic and histopathologic findings -
Exacerbation
Before first TNFα-antagonist infusion
Rheumatoid arthritis Fulfilling the 2010 ACR RA and 1987 RA criteria -
DAS28 >3.2
Gout Acute arthritis -
Urate crystal positive or previously diagnosed gout
Autoinflammatory syndrome Known history of autoinflammatory disorder -
Typical attack
Pancreatitis [20] Acute characteristic epigastric pain HIV
SIRS [17] Neutropenia (<1000/mm3)
Serum and urinary amylase levels ≥3 x ULN Chronic corticosteroid use
Compatible imaging (CT or ultrasound) findings
Infectious mononucleosis [16] Compatible clinical signs -
EBV (VCA) or CMV IgM positive
Measles [15] Febrile rash -
Measles IgM positive
Viral respiratory tract infection Symptoms/signs of respiratory tract infection Positive sputum or blood culture
Positive PCR from respiratory tract secretions
Respiratory co-infections Symptoms/signs of respiratory tract infection -
Positive PCR from respiratory tract secretions
Positive sputum or blood culture
Bacterial sepsis [17] International sepsis definition [17] HIV
Neutropenia (<1000/mm3)
Candidemia [19] Positive blood culture for Candida -
Abbreviations: ACR American College of Rheumatology, RA rheumatoid arthritis, DAS28 disease activity score, ULN upper limit of normal, EBV Epstein-Barr virus,
VCA viral capsid antigen, CMV cytomegalovirus, ICU intensive care unit.
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Cytokine and sTLR2 and sTLR4 measurement
sTLR2 and sTLR4 concentrations were measured by a
commercial ELISA kits (USCN Life Science, Inc.,
Wuhan, China) with a lower limit of detection of
0.312 ng/ml and 0.156 ng/ml, respectively. A com-
mercial ELISA (Sanquin, Amsterdam, The Netherlands)
with a minimal detection level of 1.56 pg/ml was used
for the determination of Interleukin (IL)-6 concentra-
tions in supernatants. IL-6, tumor necrosis factor
(TNF)α, IL-1Ra and IL-10 concentrations in plasma
were determined using a Luminex assay (Bio-plex cyto-
kine assay, BioRad, Hercules, CA), with a sensitivity of
6 pg/ml, 20 pg/ml, 72 pg/ml and 6 pg/ml, respectively.
CRP concentrations were measured with a commercial
ELISA, with a lower detection limit of 5 mg/l (IBL Inter-
national, Hamburg, Germany). Samples were diluted
when appropriate.
Statistical analysis
Cytokine and sTLR concentrations in the in-vitro and
endotoxemia experiments are expressed as mean ± SEM.
For the assessment of correlations Spearman correl-
ation coefficient was calculated. The Mann-Whitney
U-test was used for the comparison of two groups
in the biomarker study. Additionally, to correct for
the potential influence of age and sex on the bio-
marker concentrations, we performed multiple linear
regression analysis (forced entry method) with the
biomarker of interest as dependent variable and age,
sex and the assigned group (infection/no infection
or bacterial/viral infection) as independent variable.
Receiver operating characteristics (ROC) curve statis-
tics were applied to calculate sensitivity and specificity.
In order to determine the diagnostic accuracy of the
combination of biomarkers, logistic regression analysis
was used to estimate the predicted probabilities, which
were subsequently used for the generation of a ROC
curve. The method described by DeLong was used for
comparing areas under ROC curves (AUC) [22]. All
tests were two-sided, and P < 0.05 was considered sta-
tistically significant. Data were analyzed using Graph
Pad Prism 5 (GraphPad Software, La Jolla, CA) and
MedCalc version 11.3.1.0 (MedCalc Software, Mariakerke,
Belgium).
Table 2 Demographic characteristics of the healthy
controls and patients
Group Number Age Sex
Years (IQR) % male
Healthy controls 29 24 (20-46) 69
Crohn’s disease 15 36 (21-47) 27
Rheumatoid arthritis 20 60 (53-67) 30
Gout 36 68 (54-75) 83
Autoinflammatory syndrome 15 32 (22-42) 29
Pancreatitis 19 64 (58-72) 80
Infectious mononucleosis 16 31 (22-37) 50
Measles 43 7 (3-12) 43
Viral respiratory tract infection 25 29 (17-42) 52
Respiratory co-infections 20 11 (2-49) 70
Bacterial sepsis 49 75 (49-79) 58
Bacterial severe sepsis 50 74 (59-80) 56
Bacterial septic shock 57 72 (60-78) 56
Candidemia 26 59 (41-71) 69
Abbreviation: IQR interquartile range
Table 3 Demographic and clinical characteristics of the
patients with viral respiratory tract infections (n=25) and
bacterial respiratory tract super infections (n=20)
Variable Viral Bacterial
Male/Female (% male) 13/12 (52) 14/6 (70)
Age, yrs [median (IQR)] 29 (17-42) 11 (2-49)
Admission to the hospital ward, no (%) 14 (56) 20 (100)
ICU admission, no (%) 1 (4) 13 (65)
Comorbidities
None, no (%) 9 (36) 6 (30)
Diabetes mellitus, no (%) 1 (4) 0 (0)
Chronic obstructive pulmonary disorder or
asthma, no (%)
7 (28) 3 (15)
Chronic renal disease, no (%) 1 (4) 2 (10)
Solid or hematological malignancy, no (%) 6 (24) 6 (30)
Cardiovascular disease, no (%) 3 (12) 2 (10)
Other, no (%) 5 (20) 6 (30)
Viral pathogen
Influenza virus, no (%) 17 (68) 7 (35)
Respiratory syncythial virus, no (%) 0 (0) 6 (30)
Parainfluenza virus, no (%) 3 (12) 5 (25)
Coronavirus, no (%) 2 (8) 0 (0)
Human metapneumovirus, no (%) 1 (4) 0 (0)
Adenovirus, no (%) 0 (0) 2 (10)
Parecho-/rhinovirus, no (%) 1 (4) 0 (0)
Respiratory syncythial/rhinovirus, no (%) 1 (4) 0 (0)
Bacterial pathogen
S. aureus, no (%) 0 (0) 5 (25)
S. pneumonia, no (%) 0 (0) 3 (15)
P. aeruginosa, no (%) 0 (0) 4 (20)
S. pneumoniae/H. influenzae, no (%) 0 (0) 2 (10)
S. pneumonia/M. catarrhalis, no (%) 0 (0) 1 (5)
Other (combinations), no (%) 0 (0) 5 (25)
28-day mortality, no (%) 1 (4) 3 (15)
Abbreviations: IQR interquartile range, ICU intensive care unit.
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Results
In-vitro release of soluble TLRs by human PBMCs
sTLR2 and sTLR4 were below the detection limit (6 and
8 ng/ml, respectively) in the supernatants of unstimu-
lated PBMCs. After stimulation with LPS, Pam3Cys or
heat-killed E. coli, significant amounts of IL-6, sTLR2
and sTLR4 were released by PBMCs in the supernatant,
although shedding of sTLRs was not confined to
stimulation of its corresponding cell surface receptor
(Figure 1).
sTLR2 and sTLR4 release during human endotoxemia
sTLR2 and sTLR4 plasma concentrations displayed a
distinct pattern after LPS infusion (Figure 2). Before LPS
administration, sTLR2 and sTLR4 levels were undetect-
able or low in all volunteers. sTLR4, TNFα, IL-6 and IL-10
concentrations increased after LPS infusion and reached a
peak concentration at 2 hours LPS infusion; sTLR2
and IL-1Ra peaked after 4 hours. The mean peak
values (± SEM) were 357 ± 94 ng/ml for sTLR2, 10.5 ±
2.3 ng/ml for sTLR4, 836 ± 288 pg/ml for TNFα, 926 ±
145 pg/ml for IL-6, 90 ± 17 pg/ml for IL-10, and
26081 ± 2213 pg/ml for IL-1Ra, respectively. The AUC
of sTLR4 showed no correlation with the AUCs of sTLR2
(rs 0.03, P = 0.94), IL-6 (rs -0.07, P = 0.83), TNFα (rs -0.07,
P = 0.80), IL-10 (rs 0.22, P = 0.52), and IL-1Ra (rs 0.14,
P = 0.69). However, sTLR2 showed a strong positive correl-
ation with TNFα (rs 0.80, P = 0.003), IL-6 (rs 0.65, P = 0.03).
sTLR2 showed a trend towards a positive correlation
with IL-1Ra (rs 0.57, P = 0.06), and a negative with
IL-10 (rs -0.58, P = 0.06), respectively.
Cell-surface expression of TLR2 and TLR4 on mono-
cytes varied extensively among the subjects without a clear
pattern and did not correlate with sTLR2 and sTLR4
plasma levels (Figure 2).
Circulating concentrations of sTLR2 and sTLR4 in various
inflammatory diseases
Figure 3 shows the circulating concentrations of CRP,
sTLR2 and sTLR4 in various infectious and non-infections
inflammatory diseases. 394 patients and 29 healthy volun-
teers were included. For determination of CRP, samples of
351 patients and 11 healthy volunteers were analyzed.
CRP, sTLR2 and sTLR4 circulating concentrations were
significantly higher in patients with infection compared
with patients with non-infectious inflammation (Figure 4,
groups A and B). After correction for age and sex, the
presence of an infection was still positively associated with
CRP, sTLR2 and sTLR4: unstandardized coefficients 85
(95% CI 64-106, P < 0.001), 23 (95% CI 12-34, P < 0.001),
and 6.2 (95% CI 4.2-8.2, P < 0.001), respectively. Age,
but not sex, was also positively associated with the three
biomarker concentrations. Furthermore, compared with
patients suffering from viral infections, patients with
bacterial infections displayed higher concentrations of
CRP and sTLR4, but not sTLR2 (Figure 4, groups C and
D). Multivariate analysis with correction for age and sex
showed all three biomarkers to be independently associ-
ated with the presence of a bacterial infection. Unstan-
dardized coefficients for CRP, sTLR2 and sTLR4 were 113
(95% CI 79-147, P < 0.001), 19 (95% CI 0.2-39, P = 0.04)
and 6.2 (95% CI 2.2-9.0, P = 0.01), respectively. Neither
sex, nor age proved to influence the concentrations of
CRP, sLTR2 and sTLR4.
In the patients with bacterial or fungal sepsis, the pres-
ence of a malignancy (n = 27; without malignancy n = 155)
was associated with higher concentrations of CRP (152 vs
127 mg/l, P = 0.07), sTLR2 (62 vs 23 ng/ml, P = 0.001) and
sTLR4 (7.2 vs 4.3 ng/ml, P = 0.15), although this only
reached statistical significance for sTLR2.
The discriminative value of sTLR4 levels to identify in-
fectious versus non-infectious inflammation was similar
compared with CRP: AUC of 0.72 (95% CI 0.66-0.79)
and 0.74 (95-% CI 0.69-0.80), P = 0.80 (Table 4, Figure 5).
sTLR2 performed worse: AUC 0.60 (95% CI 0.54-0.66),
P = 0.0004 compared to the AUC of CRP. At a specificity
of 95%, circulating concentrations of sTLR2 above
47 ng/ml, sTLR4 above 18.9 ng/ml, and CRP above
150 mg/l had a sensitivity of 32%, 16% and 28%, re-
spectively, to identify an infectious process. Combin-
ation of biomarkers showed no improvement of the
AUC (Table 4).
CRP levels showed good value to discriminate between
bacterial and viral infections with an AUC of 0.94 (95%
CI 0.90-0.96). sTLR4 levels displayed a significantly
lower AUC compared with CRP: 0.75 (95% CI 0.70-0.82),
P < 0.0001. sTLR2 was a poor discriminator between pa-
tients with a bacterial or viral infection (Table 4, Figure 5).
Panel analysis with two biomarkers was comparable to the
performance of CRP alone. The cut-off values for the
Figure 1 Release of IL-6, sTLR2 and sTLR4 after stimulation for
24 hours of peripheral blood mononuclear cells with either
medium (control) several microbial stimuli. Data are expressed as
means ± SEM (n = 6). The concentrations of IL-6, sTLR2 and sTLR4
after incubation with medium are below the detection limit.
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discrimination of bacterial infections from viral infections
with a specificity of 95% were for CRP 67 mg/l (sensitivity
82%), for sTLR2 79 ng/ml (sensitivity 23%) and for sTLR4
10.6 ng/ml (sensitivity 28%).
Discussion
In the present study, we demonstrate that sTLR2 and
sTLR4 are released in-vitro and in-vivo after challenge
with microbial ligands such as LPS. Significantly elevated
plasma concentrations of sTLRs are present in the circula-
tion during experimental human endotoxemia, and high
circulating concentrations of sTLR4 are found in patients
with infections compared to patients with non-infectious
inflammation, as well as in patients with bacterial in-
fections compared with viral infections. However, the
value of sTLR2 and sTLR4 as additional diagnostic bio-
markers is low as both new markers do not surpass
CRP in accuracy.
In addition to the release of sTLR2 and sTLR4 from
stimulated immune cells [4,5], constitutive release of
sTLRs has been demonstrated in various biological fluids
such as saliva, breast milk, and amniotic fluid [10,23]. In
plasma, sTLR2 represented by several polypeptides, has
been found by others [4], although the concentrations
are low. To avoid both harmful or insufficient inflamma-
tory responses, inhibition and activation of the immune
system needs to be properly balanced. Various negative
regulators of TLRs have been described [1] of which
sTLR2 and sTLR4 constitute an important first-line
negative regulatory mechanism [4-6,23-25]. sTLR2 either
interferes with CD14-mediated triggering of membrane-
bound TLR2, dimerizes with TLR2 on the cell surface, or
competes with cellular TLR2 for microbial ligands [4].
The complex formed by sTLR4 and MD-2 probably
blocks the interaction between membrane-bound TLR4
and its ligand [25]. The rapid elevation of sTLR2 and
sTLR4 in plasma upon LPS administrations, similar to
that of pro-inflammatory cytokines, indicates that this
feedback mechanism is rapidly activated. Consistent with
our in-vitro data, the release of sTLRs in to the circulation
demonstrates that immune modulation mediated by TLRs
is not limited to the stimulation of the corresponding re-
ceptor on the cell membrane of immune cells. Since both
sTLR2 and sTLR4 dampen inflammation by disrupting
Figure 2 Mean (± SEM) plasma concentrations of TNFα, IL-6, IL-10, sTLR2, sTLR4 and IL-1Ra after administration of LPS intravenously in
11 healthy volunteers (upper 6 panels). Lower panels show mean change (± SEM) in expression of TLR2 and TLR4 on CD14+ monocytes
(mean fluorescence intensity (MFI)) compared to baseline after injection of LPS.
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TLR-mediated pro-inflammatory responses [4-6,23-25], it
might be possible that the counter regulatory mechanisms
mediated by sTLRs extend to interference with endogen-
ous TLR ligands. Although the kinetics of sTLR2 and
sTLR4 concentrations parallel those of anti-inflammatory
cytokines, quantitatively they appear to be differentially
regulated. Plasma sTLR4 levels did not show any correl-
ation with both IL-10 and IL-1Ra and for sTLR2, a nega-
tive correlation with IL-10 was found. Interestingly, while
in-vitro release of sTLR2 and sTLR4 by immune cells is
comparable, their in-vivo concentrations differ strongly,
with much higher concentration in the circulation of
sTLR2: this suggests a much more rapid clearance of
sTLR4 from circulation. This may imply that these
anti-inflammatory mechanisms are regulated at a dif-
ferent level and are potential complementary strategies
to reduce inflammation.
In recent years, an important role for TLR signaling has
been discovered in oncogenesis, particularly in inflamma-
tion-driven tumors [26]. Although the relationship between
cell-bound TLR2 and its release as a soluble form is not
clear-cut, the observed higher concentrations of sTLR2 in
the (small) group of patients with an underlying malignancy
may reflect the increased expression of TLR2 as seen in
some forms of cancer [26].
Alternatively spliced TLR4 mRNA encodes the soluble
form of TLR4 [5]. As such, we did not expect a correl-
ation between the membrane expression of TLR4 and
circulating sTLR4. On the contrary, sTLR2 results from
posttranslational processing: endocytosis of cell surface
receptor is followed by conversion into sTLR2 intracellu-
larly [4]. In previous monocyte stimulation experiments,
membrane-bound TLR2 correlated negatively with super-
natant sTLR2 [4]. We did not observe the downregulation
of cell surface TLR expression on monocytes of individ-
uals during endotoxemia. Possible explanations for this
lack of correlation are that (1) monocytes are detected
only in very low numbers at 2 hours after LPS injection
[27] and this subpopulation may well have a different
TLR expression than more active monocytes that have
Figure 3 Concentrations of CRP, sTLR2 and sTLR4 for the individual patient groups as described in the right upper panel. The median is
reported above the plots in the different figures, the number of patients under the X-axis.
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marginated at this time-point; (2) we only examined the
expression of TLRs on monocytes (CD14+), however,
other circulating cell subsets such as neutrophils or
platelets also express TLR2 [28,29], all potentially con-
tributing to the plasma concentrations of sTLRs; (3) the
soluble receptors are derived from an intracellular pool,
not directly from the cell surface [4]; and finally (4) be-
sides being shed, membrane bound TLR is influenced
by TLR trafficking between intracellular compartments
and the cell membrane [30].
An important aspect of this study is the possibility to
use soluble TLRs as diagnostic markers. Rapid and reliable
differentiation of non-infectious inflammatory disorders
from infections, and the classification of infections ac-
cording to their microbiological etiology is essential
for optimal treatment of these conditions. So far, only
a small number of studies have been published on
sTLRs as diagnostic biomarkers. A few studies from
the same group reported that intrauterine infections in
pregnant women are characterized by elevated levels of
sTLR1, sTLR2, sTLR6 and sTLR4 in the amniotic fluid
[9,10,13], supporting the concept of sTLR release during
infections. We assessed the value of sTLR2 and sTLR4
levels to discriminate between several inflammatory
Figure 4 Comparison of median plasma concentrations of CRP, sTLR2 and sTLR4 in patients with infections (A) versus non-infectious
inflammatory diseases (B) (upper panel) and in patients with a bacterial infection (C) versus a viral infection (D) (lower panels). The
Mann-Whitney U-test was used for the comparison of two groups. P-values are shown above the graphs. The median is reported above the
corresponding plot.
Table 4 AUC of the ROC for the discrimination between an infection and non-infectious inflammation and between
bacterial and viral infection
Biomarker Infection vs no infection P-value Bacterial infection vs viral infection P-value
AUC (95% CI) AUC (95% CI)
CRP 0.74 (0.69-0.80) - 0.94 (0.90-0.96) -
sTLR2 0.60 (0.54-0.66) 0.0004 0.58 (0.51-0.64) <0.0001
sTLR4 0.72 (0.66-0.79) 0.80 0.75 (0.70-0.80) <0.0001
sTLR2 + sTLR4 0.65 (0.60-0.70) 0.01 0.75 (0.69-0.80) <0.0001
sTLR2 + CRP 0.75 (0.70-0.80) 0.66 0.94 (0.90-0.96) 0.36
sTLR4 + CRP 0.76 (0.71-0.80) 0.25 0.95 (0.91-0.97) 0.13
Shown P-value for the comparisons of the AUCs with the AUC of CRP.
Abbreviations: AUC area under the curve; CI confidence interval.
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conditions. sTLR2 and sTLR4 were elevated in response
to inflammatory insults and particularly sTLR4 showed a
good specificity to discriminate between an infection and
a non-infectious inflammatory conditions such as gout,
Crohn’s disease, rheumatoid arthritis or autoinflammatory
syndromes. Moreover, sTLR4 concentrations show a high
specificity for discriminating between bacterial and viral
infections using high cut-off values, but sensitivity was
low. We have to mention however that the overall dis-
criminative value of sTLR levels was not superior to that
of CRP in the relatively small group of patients assessed in
this study Future larger validation studies should demon-
strate the overall value of sTLR2 and sTLR4 levels for the
diagnosis of infections and autoinflammatory diseases in
relation to that of classic inflammatory markers. Further-
more, besides sTLRs, other soluble pattern recognition
receptors such as the soluble mannose receptor that are
shed during cell stimulation with β-glucans are also inter-
esting candidates for new and potentially more specific
diagnostic biomarkers [31].
Our study also has limitations. Firstly, it included a
relatively limited number of clinical conditions, and it is
not possible to extrapolate our results to the entire panel
of infectious or non-infectious inflammatory diseases.
Secondly, we studied groups of inflammatory conditions
as a whole, rather than focusing on correlation with
other clinical information or outcome.
Conclusions
The present study is an important initial proof-of-
principle report on the role of sTLR2 and sTLR4 during
a broad panel of human infections and autoinflammatory
diseases. Shedding of sTLR2 and sTLR4 is not confined to
stimulation of its corresponding cell surface receptor, but
it is a broader effect upon stimulation of innate immune
cells through pattern recognition receptors. We report
the significant increase of sTLR2 and sTLR4 both in
experimental models of human endotoxemia, as well as
in the circulation of patients with infections. This suggests
an important role of soluble TLRs in the modulation of in-
flammation during infections and the potential to use
these tests as diagnostic markers. Therefore, larger valid-
ation studies in larger patient cohorts are warranted in
order to be able to draw definitive conclusions regarding
the diagnostic usefulness of sTLR2 and sTLR4 in human
inflammatory diseases.
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